WO1998017306A1 - Procede servant a augmenter les niveaux d'insuline du sang chez les mammiferes - Google Patents

Procede servant a augmenter les niveaux d'insuline du sang chez les mammiferes Download PDF

Info

Publication number
WO1998017306A1
WO1998017306A1 PCT/US1997/020414 US9720414W WO9817306A1 WO 1998017306 A1 WO1998017306 A1 WO 1998017306A1 US 9720414 W US9720414 W US 9720414W WO 9817306 A1 WO9817306 A1 WO 9817306A1
Authority
WO
WIPO (PCT)
Prior art keywords
agonist
insulin
dopamine
mammal
adrenergic
Prior art date
Application number
PCT/US1997/020414
Other languages
English (en)
Inventor
Yin Liang
Anthony H. Cincotta
Original Assignee
Ergo Research Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ergo Research Corporation filed Critical Ergo Research Corporation
Priority to AU51064/98A priority Critical patent/AU5106498A/en
Publication of WO1998017306A1 publication Critical patent/WO1998017306A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Abstract

L'invention concerne des procédés servant à augmenter les niveaux d'insuline du sang chez un mammifère et à traiter les diabétique avec des niveaux bas d'insuline du sang au moyen de l'administration d'un agoniste de dopamine.
PCT/US1997/020414 1996-10-22 1997-10-22 Procede servant a augmenter les niveaux d'insuline du sang chez les mammiferes WO1998017306A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU51064/98A AU5106498A (en) 1996-10-22 1997-10-22 Method for increasing blood insulin levels in mammals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2975896P 1996-10-22 1996-10-22
US60/029,758 1996-10-22

Publications (1)

Publication Number Publication Date
WO1998017306A1 true WO1998017306A1 (fr) 1998-04-30

Family

ID=21850730

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/020414 WO1998017306A1 (fr) 1996-10-22 1997-10-22 Procede servant a augmenter les niveaux d'insuline du sang chez les mammiferes

Country Status (2)

Country Link
AU (1) AU5106498A (fr)
WO (1) WO1998017306A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009062113A1 (fr) * 2007-11-07 2009-05-14 Burnham Institute For Medical Research Procédé et composés pour la régulation de la production d'insuline
EP3311842A1 (fr) * 2013-06-13 2018-04-25 VeroScience LLC Compositions et procédés de traitement des troubles métaboliques

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5344832A (en) * 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
US5468755A (en) * 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468755A (en) * 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
US5554623A (en) * 1988-05-10 1996-09-10 Ergo Science Incorporated Method for the long term reduction of body fat stores, insulin resistance, hypersinsulinemia and hyperglycemia in vertebrates
US5344832A (en) * 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009062113A1 (fr) * 2007-11-07 2009-05-14 Burnham Institute For Medical Research Procédé et composés pour la régulation de la production d'insuline
EP2217067A1 (fr) * 2007-11-07 2010-08-18 Burnham Institute for Medical Research Procédé et composés pour la régulation de la production d'insuline
EP2217067A4 (fr) * 2007-11-07 2011-01-19 Burnham Inst Medical Research Procédé et composés pour la régulation de la production d'insuline
US8168391B2 (en) 2007-11-07 2012-05-01 Burnham Institute For Medical Research Method for modulating insulin production
EP3311842A1 (fr) * 2013-06-13 2018-04-25 VeroScience LLC Compositions et procédés de traitement des troubles métaboliques

Also Published As

Publication number Publication date
AU5106498A (en) 1998-05-15

Similar Documents

Publication Publication Date Title
US5877183A (en) Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
US11241429B2 (en) Method of treating metabolic disorders and depression with dopamine receptor agonists
US5688794A (en) Method for modifying or regulating lipid metalolism in an animal or human subject with a proclactin stimulating compound
US6855707B2 (en) Method for the treatment of lipid and glucose metabolism disorders
CA2254116C (fr) Therapie de troubles du metabolisme des lipides et du glucose et composition afferente
WO1997041873A9 (fr) Therapie de troubles du metabolisme des lipides et du glucose et composition afferente
US5830895A (en) Methods for the determination and adjustment of prolactin daily rhythms
WO1997046239A1 (fr) Traitement des troubles du metabolisme des lipides et du metabolisme du glucose a l'aide d'antagonistes de la dopamine et de la seratonine
WO1998017306A1 (fr) Procede servant a augmenter les niveaux d'insuline du sang chez les mammiferes
JP4530433B2 (ja) 脂質及びグルコースの代謝疾患治療のための方法及び組成物
AU3101395A (en) Improved methods for the determination and adjustment of prolactin daily rhythms
Tanimoto et al. Inhibition by lithium of dopamine receptors in rat prolactin release
Tunçtan et al. Effects of econazole on receptor-operated and depolarization-induced contractions in rat isolated aorta
Ogidigben et al. Naphazoline-induced neuroendocrine changes: increases in ANP and cGMP levels, but suppression of NE, 3H-NE, and cAMP levels in rabbit eyes
Epperson Androgen-angiotensin II interactions involved in the regulation of cardiovascular function and sexual behavior
WO1999009828A1 (fr) Traitement de la phobie sociale
Papakostas et al. Effects of methysergide and ritanserin on the prolactin and thyrotropin responses to TRH in depressed patients

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA